AHP weight-loss drug settlement
AHP settles with plaintiff Debbie Lovett for less than 10% of the $23.4 mil. awarded by a jury Aug. 6 in the Texas fen-phen trial American Home Products vs. Lovett, the company confirmed Sept. 16. A nationwide settlement spanning all class action medical monitoring litigation as well as individual injury cases related to Redux (dexfenfluramine) and Pondimin (fenfluramine) may be a future strategy for the company
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth